EUCTR2017-004732-11-GB进行中（未招募）1 期
Preventing meningitis in young people after infant immunisation: effect of a single meningococcal 4CMenB vaccine booster over 10 years of age - Meningococcal B Booster Vaccine in Young People
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 117
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For recruitment to all study groups:
- •Parents/legal guardians are willing and able to comply with the requirements of the trial protocol and have internet access for the duration of the study.
- •Parents/legal guardians have given informed consent for their child’s participation in the study
- •Participant is willing and able to give informed assent for participation in the trial.
- •In the Investigator’s opinion, participants are able and willing to comply with all trial requirements.
- •Parents/legal guardians/participants are willing to allow their General Practitioner and consultant, if appropriate, to be notified of participation in the trial.
- •For recruitment to study groups 1 to 6 only
- •Male or Female, aged approximately 11 years who have completed a vaccination course of meningitis B vaccine as an infant or toddler in a previous clinical trial conducted by OVG.
- •For recruitment to Naïve groups 7 and 8 only
- •Male or Female, born between 25/06/2006 - 17/12/2006 who have not previously received meningitis vaccine
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •The participant may not enter the trial if ANY of the following apply:
- •Children of parents/legal guardians who are on the delegation log for this study
- •History of invasive meningococcal B disease
- •History of being a household contact with a case of confirmed bacterial meningitis
- •Confirmed or suspected immunodeficiency
- •A family history of congenital or hereditary immunodeficiency, or maternal HIV
- •Current receipt of more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid). Nasal, topical or inhaled steroids are allowed.
- •History of anaphylactic reaction to any component of the vaccine
- •No internet access for the duration of the study.
- •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.
- •Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
- •Prior or planned receipt of any other investigational vaccine or drug.
- •Thrombocytopenia or any bleeding disorder.
- •Receipt of blood, blood products, or plasma derivatives within the past 3 months
- •Exclusion to study groups 1 to 6 only
- •Any previous vaccination with 4CMenB vaccine except as part of V72P6, V72P6E1, V72P9 or V72P9E1 clinical trials.
- •Any previous vaccination with another meningococcal B vaccine (such as outer membrane vesicle vaccines)
- •Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 1 month or long-term systemic corticosteroid therapy (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid). However, this may be discussed on a case-by-case basis. Nasal, topical or inhaled steroids are allowed.
- •Exclusion to Naïve groups 7 and 8 only
- •Previous vaccination with 4CMenB vaccine or with any other meningococcal B vaccine (such as outer membrane vesicle vaccines)
- •Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy.
- •Current receipt of long-term systemic corticosteroid therapy (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid). Nasal, topical or inhaled steroids are allowed.
- •Long term prophylactic antibiotic use
研究者
相似试验
已完成
不适用
Meningococcal B Booster Vaccine in Young PeopleSpecialty: Infection, Primary sub-specialty: VaccinesUKCRC code/ Disease: Inflammatory and Immune System/ Certain disorders involving the immune mechanismInfections and InfestationsMeningococcal infection, unspecifiedISRCTN16774163niversity of Oxford72
已完成
不适用
Clinical care bundles for adult meningitis in MalawiBacterial meningitisPACTR201111000338157iverpool School of Tropical Medicine200
已完成
不适用
Clinical care Bundles for Adult Meningitis in MalawiISRCTN96218197iverpool School of Tropical Medicine (UK)200
已完成
不适用
Prevention of Late Onset Sepsis in infants in Neonatal Intensive CareACTRN12617000455369Mater Mothers' Hospital250
进行中（未招募）
1 期
PREVENTING CHOLESTASIS IN PREMATURE INFANTS USING SMOFLIPID•To compare a mixed parenteral lipid emulsion containing fish oil (SMOFlipid®) with a soybean oil based lipid emulsion (Intralipid®) for its effect on the occurrence of parenteral nutrition associated cholestasis in extremely low birth weight infantsEUCTR2011-005456-33-ATMed. Univ. Wien, Universitätsklinik für Kinder- und Jugendheilkunde200